HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 285/6/G1345    most recent 00374.2002v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Ramsanahie, A. Articles by Whang, E. E. Search for Related Content PubMed PubMed Citation Articles by Ramsanahie, A. Articles by Whang, E. E.

MUCOSAL BIOLOGY

Effect of GLP-2 on mucosal morphology and SGLT1 expression in tissue-engineered neointestine

¹Department of Surgery, Brigham and Women's Hospital, and ²Department of Surgery and ³Division of Endocrinology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02115

Submitted 30 August 2002 ; accepted in final form 2 August 2003

Using tissue-engineering techniques, we have developed a neointestine that regenerates the structural and dynamic features of native small intestine. In this study, we tested neointestinal responsiveness to glucagon-like peptide 2 (GLP-2). Neointestinal cysts were engineered by seeding biodegradable polymers with neonatal rat intestinal organoid units. The cysts were matured and anastomosed to the native jejunum of syngeneic adult recipients. Animals were treated with GLP-2 [Gly²] (twice daily, 1 µg/g body wt) or vehicle alone (control) for 10 days. Rats were then killed, and tissues were harvested for analysis. Na⁺-glucose cotransporter (SGLT1) mRNA expression was assessed with Northern blotting and in situ hybridization. SGLT1 protein was localized by using immunofluorescence. GLP-2 administration resulted in 1.8- and 1.7-fold increases (P < 0.05) in neointestinal villus height and crypt depth, respectively. GLP-2 administration also resulted in a 2.4-fold increase (P < 0.01) in neomucosal SGLT1 mRNA expression. SGLT1 mRNA expression was localized to enterocytes throughout the villi, and SGLT1 protein was localized to the brush border of enterocytes along the entire length of villi from the neointestine of GLP-2-treated animals. The response of tissue-engineered neointestine to exogenous GLP-2 includes mucosal growth and enhanced SGLT1 expression. Therefore, tissue-engineering principles may help in dissecting the regulatory mechanisms mediating complex processes in the intestinal epithelium.

tissue engineering; neomucosa; glucagon-like peptide-2; sodium-glucose cotransporter 1

This article has been cited by other articles:

				P. E. Dube and P. L. Brubaker Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators Am J Physiol Endocrinol Metab, August 1, 2007; 293(2): E460 - E465. [Abstract] [Full Text] [PDF]

				P B Jeppesen, E L Sanguinetti, A Buchman, L Howard, J S Scolapio, T R Ziegler, J Gregory, K A Tappenden, J Holst, and P B Mortensen Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients Gut, September 1, 2005; 54(9): 1224 - 1231. [Abstract] [Full Text] [PDF]

				A. Perez, M. Duxbury, F. G. Rocha, A. P. Ramsanahie, R. S. Farivar, H. Varnholt, H. Ito, H. Wong, J. Rounds, M. J. Zinner, et al. Glucagon-Like Peptide 2 Is an Endogenous Mediator of Postresection Intestinal Adaptation JPEN J Parenter Enteral Nutr, March 1, 2005; 29(2): 97 - 101. [Abstract] [Full Text] [PDF]